Skip to main content
Harbour BioMed partner plans $50 million Adrenyx funding
Image for illustrative purposes only. Not a real photo.

Harbour BioMed partner plans $50 million Adrenyx funding

By

Key points

  • Harbour BioMed's partner Spruce Biosciences separated its CRHX-101 antibody programme into Adrenyx Biosciences, a new subsidiary focused on endocrine disorders.
  • Adrenyx secured an initial US$5 million in convertible note financing, with a planned equity financing of up to US$50 million, inclusive of the note funding.
  • Adrenyx is expected to list on Nasdaq in the first half of 2027, while Harbour BioMed expects to hold equity interests in both companies following a planned share distribution.

Harbour BioMed announced that its partner Spruce Biosciences (NASDAQ:SPRB) has separated its CRHX-101 antibody programme into Adrenyx Biosciences, a wholly owned subsidiary expected to become a separately listed company in the first half of 2027.

CRHX-101 is an investigational monoclonal antibody designed to neutralise corticotropin-releasing hormone (CRH), an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disorder.

Adrenyx secured an initial US$5 million through secured convertible notes, with the facility allowing up to US$10 million in total notes, while a planned private placement could provide up to US$50 million from the same institutional investor, inclusive of the note funding, to support nonclinical studies, manufacturing preparations and a future FDA Investigational New Drug application.

CRHX-101 originated from HBM Alpha Therapeutics, a biotechnology company incubated by Harbour BioMed, which licensed the programme to Spruce in January 2025 for development and commercialisation outside Greater China, under an agreement offering up to US$395 million in milestone payments and tiered royalties on future product sales.

Following the planned pro rata distribution of Adrenyx shares to Spruce shareholders, Harbour BioMed expects to hold equity interests in both companies, extending its biotechnology partnership strategy across antibody development, immunology, oncology and other therapeutic areas.


Frequently asked questions